The E3 ubiquitin ligase Smurf2 mediates ubiquitination and degradation of several protein targets involved in tumorigenesis and induces senescence in human cells. However, the functional role of Smurf2 in tumorigenesis has not been fully evaluated. In this study, we generated a mouse model of Smurf2 deficiency to characterize the function of this E3 ligase in tumorigenesis. Smurf2 deficiency attenuated p16 expression and impaired the senescence response of primary mouse embryonic fibroblasts. In support of a functional role in controlling cancer, Smurf2 deficiency increased the susceptibility of mice to spontaneous tumorigenesis, most notably B-cell lymphoma. At a premalignant stage of tumorigenesis, we documented a defective senescence response in the spleens of Smurf2-deficient mice, consistent with a mechanistic link between impaired senescence regulation and increased tumorigenesis. Taken together, our findings offer the genetic evidence of an important tumor suppressor function for Smurf2. Cancer Res; 72(11); 2714–9. ©2012 AACR.
The E3 ubiquitin ligase Smurf2 has been shown to mediate ubiquitination of several proteins, including components of the TGF-β and Wnt signaling, Runx2, Rap1B, Smurf1, and Id1 (1–11). These diverse substrates suggest that Smurf2 is involved in many biologic processes. We have previously shown that Smurf2 expression increases in response to telomere shortening in senescent cells (12). Furthermore, we have discovered that Smurf2 recruits both the p53 and pRb pathways to activate senescence (13), suggesting that Smurf2 is a critical regulator of senescence. As an important tumor suppressor mechanism, senescence restricts the proliferation of cells at risk of malignant transformation (14, 15). Consistent with this model, we have found that upregulation of Smurf2 leads to growth arrest in various tumor cells (16).
Despite the advance in our understanding of the molecular function of Smurf2, the precise role of Smurf2 in tumorigenesis has not been established. In this study, we generated a mouse model of Smurf2 deficiency and showed that Smurf2 deficiency leads to an impaired senescence response in primary cells. Consistent with its function in senescence regulation, Smurf2-deficient mice exhibited increased spontaneous tumorigenesis, indicating that Smurf2 functions as a tumor suppressor.
Materials and Methods
Mouse embryonic stem (ES) cell line RRA098 was purchased from Mutant Mouse Regional Resource Center at University of California-Davis (Davis, CA). ES cells were injected into C57BL/6 blastocysts to obtain chimeric mice, which were bred to generate Smurf2-deficient mice. Mouse cohorts on a mixed 129OlaxC57BL/6 background were monitored, and moribund mice were sacrificed for necropsy. Paraffin-embedded tissue sections were stained for hematoxylin and eosin and B220 (Abcam). Frozen sections were fixed, stained for senescence-associated β-galactosidase (SA-β-gal) activity (13), and counterstained with eosin. Mouse studies were approved by the Institutional Animal Care and Use Committee of University of Massachusetts Medical School (Worcester, MA).
Assays of mouse embryonic fibroblasts
Mouse embryonic fibroblasts (MEF) were prepared from E12.5 embryos and cultured as described (17). To analyze cell proliferation, MEFs were seeded in 6-well plates, harvested in triplicate, and counted daily using a Particle Counter (Beckman Coulter). In senescence assay, MEFs were plated in 10-cm dish and subcultured every 3 days before they reached high cell density. In 3T9 immortalization assay, MEFs were plated at 3 × 106 per 10-cm dish in triplicate and passaged every 3 days.
MEFs were infected with lentivirus-expressing Smurf2 or GFP as previously described (16) and stained with crystal violet or SA-β-gal activity (13) after selection with puromycin. To analyze DNA damage response, MEFs were treated with 1 μmol/L doxorubicin (Sigma), and cell lysates were collected for Western blotting.
Genomic DNA was extracted using genomic DNA isolation kit (Lamda Biotech), digested with restriction enzymes (New England Biolabs), electrophoresed in agarose gel, and transferred to Hybond nylon membrane (GE Healthcare). Probe labeling, hybridization, and detection were carried out using DIG-High Prime DNA Labeling and Detection Starter Kit (Roche).
Total RNA was isolated using RNeasy Mini Kit (Qiagen), and reverse-transcribed using Superscript II (Invitrogen). Real-time PCR was carried out using SYBR Green PCR Kit (Bio-Rad) with the following primers: Smurf2 (5′-ATGAAGTCATTCCCCAGCAC-3′; 5′-AACCGTGCTCGTCTCTCTTC-3′), p16 (5′-CGAACTCTTTCGGTCGTACCC-3′; 5′-CGAATCTGCACCGTAGTTGAG-3′), or β-actin (5′-GCTCTTTTCCAGCCTTCCTT-3′; 5′-GTGCTAGGAGCCAGAGCAGT-3′).
Genomic DNA was used in real-time PCR to determine the relative abundance of the Smurf2 alleles with the following primers: wild-type Smurf2 (5′-GAGGGTGTTGGTGAGAGGAA-3′; 5′-TTACACAGCATCTGGCAAGG-3′), trapped Smurf2 (5′-GAGGGTGTTGGTGAGAGGAA-3′; 5′-GACAAGTAGATCCCGGCGCTC-3′), or GAPDH (5′-AGCCTTAAAAGCCCTTGAGC-3′; 5′-CTAGGAAGAGGGGGAGAGGA-3′).
Western blotting was carried out as described (11) with the following antibodies: Smurf2 (Epitomics); p53 (Calbiochem); α-tubulin (Sigma); and p16, p19, p21, and GAPDH (Santa Cruz Biotechnology).
Kaplan–Meier survival curves were plotted and analyzed with the log-rank test. The Student t test (2-tailed and unpaired) was used for pairwise comparisons.
A mouse model of Smurf2 deficiency
We used a mouse ES cell line RRA098 with a gene-trapping vector (pGT1lxf) inserted into intron 1 of Smurf2 (Fig. 1A) to generate a mouse model of Smurf2 deficiency. A single integration of the trapping vector in RRA098 genome was observed in Southern blot analysis (Fig. 1B) and further determined by sequencing analysis (Supplementary Fig. S1A and Table S1). Smurf2 transcripts were increased in ES cells after Cre-mediated excision of loxP-flanked splicing acceptor (SA; Fig. 1C), indicating that Smurf2 expression is compromised in RRA098 cells, and removal of SA restores its expression.
Mice heterozygous for the trapped allele (Smurf2+/T) were viable and developmentally normal. Intercrossing of Smurf2+/T mice generated Smurf2T/T mice with expected Mendelian frequency (36:72:35 for Smurf2+/+:Smurf2+/T:Smurf2T/T) and grossly normal development (Supplementary Fig. S2). Smurf2 expression in Smurf2+/T MEFs or embryos was reduced to approximately 50% of wild-type, whereas Smurf2 (∼20%) was still detected in Smurf2T/T MEFs or embryos (Fig. 1D; Supplementary Fig. S1C), suggesting that this trapped allele is hypomorphic. Consistent with this notion, Smurf2 expression was reduced but not absent in many tissues of Smurf2T/T mice compared with wild-type littermates (Fig. 1E). The Smurf2T/T mouse thus serves as a model of Smurf2 deficiency.
Impaired senescence response in Smurf2-deficient MEFs
At early passage, no obvious difference in cell proliferation was noted among MEFs of different genotypes (Fig. 2A). However, senescence entry was delayed in Smurf2T/T and Smurf2+/T MEFs compared with wild-type (Fig. 2B). We next passaged MEFs with a 3T9 protocol starting from passage 2. Wild-type MEFs entered senescence around passage 7. In contrast, Smurf2T/T and even some Smurf2+/T MEFs showed a tendency to become immortalized and continued to proliferate beyond passage 20 (Fig. 2C), indicating that Smurf2 deficiency promotes spontaneous immortalization of primary fibroblasts.
To assess whether immortalization of Smurf2T/T MEFs is the result of Smurf2 deficiency or caused by secondary mutations in other genes, we tested whether Smurf2 can induce senescence in these MEFs. Ectopic expression of Smurf2 or a ligase mutant C716A (13) induced senescence in early and late passage already immortalized Smurf2T/T MEFs (Supplementary Fig. S3), suggesting that Smurf2 is essential for senescence. Furthermore, we found that p53 and p21CIP1/WAF1 (p21) increased in early-passage and immortalized Smurf2T/T MEFs after doxorubicin treatment (Fig. 2D), indicating that Smurf2-deficient MEFs have a functional DNA damage response, and immortalization of Smurf2T/T MEFs is independent of p53 loss.
To further investigate the mechanism underlying the impaired senescence response in Smurf2-deficient MEFs, we examined the expression of known senescence regulators during serial passage. No obvious change in the expression of p19Arf (p19), p21, or p53 was observed between wild-type and Smurf2T/T MEFs (Fig. 2E). Consistent with our recent finding that Smurf2 regulates p16INK4a (p16) expression through ubiquitination of Id1 (11), p16 expression in early-passage Smurf2T/T MEFs was decreased compared with wild-type MEFs. While p16 expression was elevated in late-passage wild-type MEFs, this p16 elevation was significantly attenuated in Smurf2T/T MEFs (Fig. 2E), suggesting a mechanistic link between inhibition of p16 expression and delayed senescence in Smurf2-deficient MEFs.
Increased spontaneous tumorigenesis in Smurf2-deficient mice
Smurf2T/T (30.6%) and Smurf2+/T (23.8%) mice developed tumors spontaneously within 20 months, whereas no tumor was found in wild-type mice within the same period (Fig. 3A). All affected Smurf2-deficient mice had enlarged spleens (Fig. 3B) and developed lymphomas. A majority of lymphomas (82.4%) stained strongly for B220 (Fig. 3C; Supplementary Fig. S4), indicating a B-cell origin. The lymphomas often spread to other organs: 47.1% and 23.5% of mice with lymphoma in spleen were found to have lymphoma in kidney and liver, respectively (Fig. 4C; Supplementary Fig. S5). In addition to lymphoma (72.7% of tumors), we also found other types of tumors, including hepatocellular carcinoma (13.6%), adenocarcinoma in small intestine (4.5%), and sarcoma (9.1%; Fig. 3D). Collectively, these results indicate that Smurf2 deficiency leads to increased spontaneous tumorigenesis in mice and suggest that Smurf2 functions as a tumor suppressor.
Increased spontaneous tumorigenesis was also observed in Smurf2+/T mice, which had approximately 50% of Smurf2 protein. Interestingly, 3 of the 4 lymphoma samples from Smurf2+/T mice showed lower level of Smurf2 protein than normal spleen of Smurf2+/T mice (Supplementary Fig. S6A). To test whether LOH occurred during development of these lymphomas, we used quantitative PCR to compare the abundance of the wild-type and trapped Smurf2 alleles with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in tail and spleen (Supplementary Fig. S6). Three lymphoma samples from Smurf2+/T mice with decreased Smurf2 protein levels showed a reduction in the abundance of the wild-type Smurf2 allele compared with unaffected corresponding tail DNA (Supplementary Fig. S6D), whereas the relative abundance of the trapped Smurf2 allele was either unchanged or increased (Supplementary Fig. S6E). These results suggest a loss of the wild-type Smurf2 allele in these lymphomas and confirm that loss of Smurf2 results in the formation of tumors in mice.
Senescence regulation in spleens of Smurf2-deficient mice
As the majority of tumors found in Smurf2-deficient mice were B-cell lymphomas in spleen, we investigated whether senescence response was impaired in spleens of Smurf2-deficient mice. In 12-month-old premalignant mice, we found positive staining for SA-β-gal activity in spleens of wild-type mice, whereas such positive staining was largely absent in spleens of Smurf2T/T mice (Fig. 4A), indicating an impaired senescence response in spleens of Smurf2-deficient mice. Consistent with our recent finding that Smurf2 regulates p16 expression through ubiquitination and degradation of Id1 during senescence (11), we found that Id1 was elevated, whereas p16 expression was decreased in spleens of 12-month-old premalignant Smurf2T/T mice compared with age-matched wild-type littermates (Fig. 4B). These results suggest that the Smurf2/Id1/p16 axis regulates senescence in vivo. As senescence acts as an important tumor suppressor to restrict the proliferation of cells at risk of malignant transformation (14, 15), an impaired senescence response in Smurf2-deficient cells provides an underlying mechanism of increased spontaneous tumorigenesis in Smurf2-deficient mice.
In this study, we found that Smurf2-deficient mice exhibited an increased susceptibility to spontaneous tumorigenesis, indicating that Smurf2 has a tumor suppression function. Further support for Smurf2 as a tumor suppressor is the observation of increased spontaneous tumorigenesis in Smurf2+/T mice accompanied by frequent loss of the wild-type Smurf2 allele in these tumors. Consistent with this notion, Smurf2 mutations have been found in human melanoma (2 of 8) and lung carcinoma (1 of 145) samples in COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic). The identified nonsense mutations (1222C>T, R408* or 1774C>T, R592*) would result in truncated Smurf2 proteins lacking a functional HECT domain, thus disrupting its function as an E3 ubiquitin ligase and its ability to induce senescence (13). Collectively, these observations support the notion that Smurf2 is a tumor suppressor.
Increased tumorigenesis was preceded by an impaired senescence response in spleens and primary fibroblasts of Smurf2-deficient mice. Meanwhile, apoptosis as determined by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining was not altered in Smurf2-deficient lymphomas or precancerous spleens compared with wild-type (data not shown). Consistent with our recent finding that Smurf2 ubiquitinates Id1 to regulate p16 expression during senescence in culture (11), we found elevation of Id1 and corresponding decrease in p16 expression in spleens of premalignant Smurf2-deficient mice, suggesting that the Smurf2/Id1/p16 axis regulates senescence response in vivo. Emerging evidence indicates that senescence is an important tumor suppressor mechanism by restricting proliferation of cells at risk of neoplastic transformation (14, 15). Our current study provides a mechanistic link between Smurf2-mediated senescence regulation and its role as a tumor suppressor in vivo.
Smurf2 is suggested to target Smads and TGF-β receptor for ubiquitination and degradation (1–3). However, these cell culture studies are challenged by recent studies of Smurf2 knockout mice, which indicate that Smurf2 does not regulate protein stability of Smads and TGF-β receptor under physiologic conditions in vivo (9, 18). Smurf2 has also been implicated to ubiquitinate both negative (Axin and GSK-3β) and positive (β-catenin) regulators of the canonical Wnt signaling pathway (4, 8, 10). Studies of Smurf1/2 double knockout mice reveal that Smurf2 instead regulates the noncanonical Wnt signaling through ubiquitination of Prickle1 (9). We have recently discovered that Smurf2 ubiquitinates Id1 (11), which is involved in diverse cellular processes including proliferation, differentiation, and angiogenesis (19). It will be interesting to determine whether Smurf2-mediated ubiquitination of any of these or other yet unidentified protein substrates, in addition to senescence regulation, plays an important role in its function as a tumor suppressor.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Conception and design: C. Ramkumar, H. Zhang
Development of methodology: C. Ramkumar, R.M. Gerstein, H. Zhang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Ramkumar, Y. Kong, H. Cui, S.N. Jones, H. Zhang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Ramkumar, Y. Kong, H. Cui, S. Hao, R.M. Gerstein, H. Zhang
Writing, review, and/or revision of the manuscript: C. Ramkumar, S.N. Jones, R.M. Gerstein, H. Zhang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Zhang
Study supervision: H. Zhang
This work was supported by grants from the National Cancer Institute (R01CA131210) and The Ellison Medical Foundation (AG-NS-0347-06) to H. Zhang. The UMMS Histology-Morphology Core supported by a DERC grant (DK32520) from NIH/NIDDK was used.
The authors thank Laura Fineman, Ivan Lebedev, and the UMMS Transgenic Animal Modeling Core for technical assistance.
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
Note: While the manuscript was in revision, Smurf2 as a tumor suppressor was independently reported (Blank and colleagues, ref. 20).
- Received November 18, 2011.
- Revision received March 7, 2012.
- Accepted April 9, 2012.
- ©2012 American Association for Cancer Research.